Evidence map›Paper›PMID 42436853›Full record

ArticleMolecular therapy. Advances2026

Sindbis virus self-amplifying replicon is compatible with modified nucleotides mediating expression and vaccine responses

Hiva Azizi, Gerard Agbayani, Tyler M Renner, Bryan Simard, Umar Iqbal, Renu Dudani, Yimei Jia, Michael J McCluskie, Bassel Akache

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hiva AziziNational Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada.
Gerard AgbayaniNational Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada.
Tyler M RennerNational Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada.
Bryan SimardNational Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada.
Umar IqbalNational Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada.
Renu DudaniNational Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada.
Yimei JiaNational Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada.
Michael J McCluskieNational Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada.
Bassel AkacheNational Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advent of effective formulations based on RNA encapsulated within lipid nanoparticles has led to the evaluation of this technology for its ability to treat and prevent a wide range of diseases. Expansion of the RNA-based tool kit available to vaccine and drug developers will accelerate this development and hopefully produce more robust and cost-effective therapies. With its more sustained expression profile, self-amplifying RNA offers many advantages to standard messenger RNA, allowing for the administration of lower RNA doses

Indexed as

alphaviruslipid nanoparticlesmodified nucleotidesRNA therapeuticsRNA vaccinesself-amplifying RNAself-replicating RNASindbisSINVVEEV

Identifiers

PMID42436853
PMCPMC13355167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.